Cargando…

Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA

OBJECTIVES: We aimed to study the racial differences in clinical presentations, survival outcomes and outcome predictors among patients with heart failure (HF) with midrange ejection fraction (HFmrEF, EF 40%–49%). DESIGN: This is a retrospective study. SETTING: Adults with HF diagnosis at Montefiore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dan Leslie, Quispe, Renato, Onyekwelu, Chioma, Faillace, Robert T, Taub, Cynthia C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501992/ https://www.ncbi.nlm.nih.gov/pubmed/31048442 http://dx.doi.org/10.1136/bmjopen-2018-026479

Ejemplares similares

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

CMR Tissue Characterization in Patients with HFmrEF
por: Doeblin, Patrick, et al.
Publicado: (2019)

Obesity increases cardiovascular mortality in patients with HFmrEF
por: Liu, Zhican, et al.
Publicado: (2022)

Impact of signs and symptoms on the prognosis of patients with HFmrEF
por: Liu, Zhican, et al.
Publicado: (2023)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group?()
por: Webb, Jessica, et al.
Publicado: (2018)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

Risk factors of short‐term, intermediate‐term, and long‐term cardiac events in patients hospitalized for HFmrEF
por: Zhu, Yunlong, et al.
Publicado: (2022)

Ejection fraction at hospital admission stratifies mortality risk in HFmrEF patients aged ≥ 70 years: a retrospective analysis from a tertiary university institution
por: Sonaglioni, Andrea, et al.
Publicado: (2023)

Aging-Related Endothelial Progenitor Cell Dysfunction and Its Association with IL-17 and IL-23 in HFmrEF Patients
por: Zeng, Lijin, et al.
Publicado: (2022)

Clinical Characteristics of Young Patients With Heart Failure With Reduced Ejection Fraction in a Racially Diverse Cohort
por: Zepeda, Ignacio, et al.
Publicado: (2019)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature
por: Hu, Yang, et al.
Publicado: (2018)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction
por: Nadruz, Wilson, et al.
Publicado: (2017)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Follow‐up after hemodynamically not tolerated ventricular tachycardia in patients with midrange reduced to normal ejection fraction: A retrospective single‐centre case series
por: Groeneveld, Sanne A., et al.
Publicado: (2020)

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis
por: Lebedev, D. A., et al.
Publicado: (2020)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction
por: Alaarag, Ahmed Farouk, et al.
Publicado: (2021)

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
por: Chen, Yei-Tsung, et al.
Publicado: (2019)

Ventricular arrhythmias not meeting criteria for terminating cardiopulmonary exercise testing stratify prognosis and disease severity in heart failure of preserved, midrange, and reduced ejection fraction
por: Popovic, Dejana, et al.
Publicado: (2020)

Surgical treatment of patients with aortic valve disease complicated with moderate functional mitral regurgitation and heart failure with midrange ejection fraction: a cohort study
por: Zhao, Wei, et al.
Publicado: (2022)

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries
por: Choi, Ki Hong, et al.
Publicado: (2018)

Left Ventricular Remodeling Risk Predicted by Two-Dimensional Speckle Tracking Echocardiography in Acute Myocardial Infarction Patients with Midrange or Preserved Ejection Fraction in Western Romania
por: Bordejevic, Diana Aurora, et al.
Publicado: (2021)

Magnetostriction Enhancement in Midrange Modulus Magnetorheological Elastomers for Sensor Applications
por: Tasin, Muhammad Asyraf, et al.
Publicado: (2023)

The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial
por: Alzahrani, Talal, et al.
Publicado: (2018)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
por: Singh, Ajmer, et al.
Publicado: (2018)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Racial differences and mortality risk in patients with heart failure and hyponatremia
por: Miles, Jeremy A., et al.
Publicado: (2019)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
por: Chen, Liling, et al.
Publicado: (2022)

Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
por: Schulz, Lisa, et al.
Publicado: (2022)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
por: Valero-Muñoz, María, et al.
Publicado: (2022)

Deciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF)
por: Jyotsna, FNU, et al.
Publicado: (2023)

Ejection fraction (EF) corrected volumetric parameters better reflect preload and fluid responsiveness
por: Malbrain, M, et al.
Publicado: (2004)

Obesity and heart failure with preserved ejection fraction (HFprEF): the whole body question
por: eBioMedicine
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8gc19kiofjee4j3gfm16t0bjnf